Effects of Isosakuranetin on Pharmacokinetic Changes of Tofacitinib in Rats with N-Dimethylnitrosamine-Induced Liver Cirrhosis

Tofacitinib, a Janus kinase 1 and 3 inhibitor, is used to treat rheumatoid arthritis. It is mainly metabolized by the cytochromes p450 (CYP) 3A1/2 and CYP2C11 in the liver. Chronic inflammation eventually leads to cirrhosis in patients with rheumatoid arthritis. Isosakuranetin (ISN), a component of...

Descripción completa

Detalles Bibliográficos
Autores principales: Bae, Sung Hun, Choi, Hyeon Gyeom, Park, So Yeon, Chang, Sun-Young, Kim, Hyoungsu, Kim, So Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783783/
https://www.ncbi.nlm.nih.gov/pubmed/36559177
http://dx.doi.org/10.3390/pharmaceutics14122684

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783783/
https://www.ncbi.nlm.nih.gov/pubmed/36559177
http://dx.doi.org/10.3390/pharmaceutics14122684

Ejemplares similares